Abstract: A filter membrane has at its flow in side a first metal fiber web, at least two metal fiber layers, and a fine and at least one coarser fiber layer. The fine fiber layer is located at the flow in side of the filter membrane and the at least one coarser fiber layer is located downstream of the fine fiber layer. The filter membrane has at its flow out side, a stack of one or more first two-dimensional metal structures with constant and regular openings. The filter membrane also has at least one set formed by a second metal fiber web and a stack of one or more second two-dimensional metal structure with constant and regular openings; the at least one set is provided in between the stack of one or more two-dimensional metal structures that are having constant and regular openings, and the first metal fiber web.

Abstract: A filter membrane has at its flow in side a first metal fibre web, at least two metal fibre layers, and a fine and at least one coarser fibre layer. The fine fibre layer is located at the flow in side of the filter membrane and the at least one coarser fibre layer is located downstream of the fine fibre layer. The filter membrane has at its flow out side, a stack of one or more first two-dimensional metal structures with constant and regular openings. The filter membrane also has at least one set formed by a second metal fibre web and a stack of one or more second two-dimensional metal structure with constant and regular openings; the at least one set is provided in between the stack of one or more two-dimensional metal structures that are having constant and regular openings, and the first metal fibre web.

Abstract: The present invention is directed to novel pharmaceutical compositions comprising nano- and micro-particulate formulations of poorly water soluble tubulin inhibitors of the indole chemical class, preferably N-substituted indol-3-glyoxyamides, and more preferably N-(Pyridin-4-yl)-[1-(4-chlorobenzyl)-indol-3-yl]glyoxylic acid amide (D-24851), also known as “Indibulin,” and methods of making and using such compositions for the treatment of anti-tumor agent resistant cancers and other diseases.

Abstract: The present invention relates to compositions of submicron- to micron-size particles of antimicrobial agents. More particularly the invention relates to a composition of an antimicrobial agent that renders the agent potent against organisms normally considered to be resistant to the agent. The composition comprises an aqueous suspension of submicron- to micron-size particles containing the agent coated with at least one surfactant selected from the group consisting of: ionic surfactants, non-ionic surfactants, biologically derived surfactants, and amino acids and their derivatives. The particles have a volume-weighted mean particle size of less than 5 ?m as measured by laser diffractometry.

Abstract: The present invention is directed to novel pharmaceutical compositions comprising nano- and micro-particulate formulations of poorly water soluble tubulin inhibitors of the indole chemical class, preferably N-substituted indol-3-glyoxyamides, and more preferably N-(Pyridin-4-yl)-[1-(4-chlorobenzyl)-indol-3-yl]glyoxylic acid amide (D-24851), also known as “Indibulin,” and methods of making and using such compositions for the treatment of anti-tumor agent resistant cancers and other diseases.

Abstract: Disclosed is an improved sustained release drug delivery device and method of producing such device. The device comprises a drug core in an impermeable cup or impermeable coating layer that is adhered to an uncured suture tab and covered with a permeable polymer coating layer that is similar to the makeup of the suture tab. The permeable polymer coating layer that covers the device, covering the impermeable coating layer and at least a portion of the drug core, is cured (after drying) along with the uncured suture tab. The “cocuring” or one step curing process forms a very strong bond between the outer coating layer to the suture tab preventing leaks.

Abstract: Disclosed is an improved sustained release drug delivery device and method of producing such device. The device comprises a drug core in an impermeable cup or impermeable coating layer that is adhered to an uncured suture tab and covered with a permeable polymer coating layer that is similar to the makeup of the suture tab. The permeable polymer coating layer that covers the device, covering the impermeable coating layer and at least a portion of the drug core, is cured (after drying) along with the uncured suture tab. The “cocuring” or one step curing process forms a very strong bond between the outer coating layer to the suture tab preventing leaks.

Abstract: The present invention relates to compositions of submicron- to micron-size particles of antimicrobial agents. More particularly the invention relates to a composition of an antimicrobial agent that renders the agent potent against organisms normally considered to be resistant to the agent. The composition comprises an aqueous suspension of submicron- to micron-size particles containing the agent coated with at least one surfactant selected from the group consisting of: ionic surfactants, non-ionic surfactants, biologically derived surfactants, and amino acids and their derivatives. The particles have a volume-weighted mean particle size of less than 5 ?m as measured by laser diffractometry.

Abstract: The present invention is directed to an improved sustained release drug delivery device comprising a drug core, a unitary cup, and a permeable plug.

Abstract: The present invention is directed to an improved sustained release drug delivery device comprising a drug core, a unitary cup, and a permeable plug.

Abstract: The present invention is directed to an improved sustained release drug delivery device for delivering multiple agents comprising a drug core, a unitary cup, and a permeable plug.

Abstract: The present invention relates to compositions of submicron-to micron-size particles of antifungal agents. More particularly the invention relates to aqueous suspensions of antifungal agents for pharmaceutical use.

Abstract: The present invention is directed to an improved sustained release drug delivery device for delivering multiple agents comprising a drug core, a unitary cup, and a permeable plug.

Abstract: The present invention is directed to an improved sustained release drug delivery device comprising a drug core, a unitary cup, and a permeable plug.

Abstract: Disclosed is an improved sustained release drug delivery device and method of producing such device. The device comprises a drug core in an impermeable cup or impermeable coating layer that is adhered to an uncured suture tab and covered with a permeable polymer coating layer that is similar to the makeup of the suture tab. The permeable polymer coating layer that covers the device, covering the impermeable coating layer and at least a portion of the drug core, is cured (after drying) along with the uncured suture tab. The “cocuring” or one step curing process forms a very strong bond between the outer coating layer to the suture tab preventing leaks.